Among them, Wilms’ tumor 1 (WT1) has probably accumulated the most relevant evidence in the clinical setting, but also other target antigens, such as Proteinase-3 (PR3), preferentially expressed antigen of melanoma (PRAME) and receptor for hyaluronic acid-mediated motility (RHAMM) have been explored and are under clinical investigation for the treatment of AML. This evidence concerns the gene PRTN3 and acute myeloid leukemia.